Diet and stress effects on omalizumab response in chronic hives
Part of Immune system & allergy, Skin clinical trials.
This study looks at how diet and oxidative stress (a type of cell damage) affect the severity of chronic hives and how well patients respond to the medication omalizumab (Xolair). It may help find ways to improve treatment by understanding these factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with chronic spontaneous urticaria (ongoing hives for at least 6 weeks).
- You do not have any other major health conditions like diabetes, inflammatory diseases, or cancer.
- You have not used anti-inflammatory drugs or medications that affect blood sugar or cholesterol in the last 3 months.
- You are not a smoker or regular alcohol drinker, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a bacterial lysate medicine (OM-85) combined with allergy medication can better control chronic hives in people whose regular allergy pills aren't working well enough. You'll be observed over time to see if this combination is safe and effective.
This study follows patients with severe asthma or chronic hives who are already on omalizumab (Xolair) and are switching to a very similar, lower-cost biosimilar called OMLYCLO. It aims to see if the switch works well in real-world practice.
This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.
This trial tests a new tablet (Alpha-0261) for chronic spontaneous urticaria (long-lasting hives without a clear cause). It aims to see if the drug is safe and tolerable. Part 1 includes people with chronic hives, and Part 2 looks at how food affects the drug in healthy adults.
Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.